Table of Contents

Oral communications

P029 Frequency of measuring body weight in (sub)populations of patients with cancer treated with chemotherapy

S. Kemps¹, M. Soleyman¹, H. Huls¹, M. Labots², M. Crul¹

P037 A single experience with palbociclib toxicity requiring dose modifications and its impact on the efficacy

M. Del Vecchio¹, V. Ladisa¹, F. Zelante¹, E. Cataldo¹, F. Chinotti¹, C. L. Pantano¹

P050 Effectiveness and safety of durvalumab for advanced non cell lung cancer

L. Ulacia Epelde¹, A. Ros Olaso¹, I. Beristain Aramendi¹, J. Boo Rodriguez¹, T. Gonzalez Fernandez¹, G. Lizeaga Cundin¹, M. Josune Garcia de Andoin Barandiaran¹, G. Lopez Arzoz¹, A. Eceiza Diez1, C. Andueza Granados¹, M. Pilar Bachiller Cacho¹

P109 Extended in-use stability of the generic nab-paclitaxel medicine Pazenir®

R. Terkola¹, C. N. Julia Pietrzak², A. S.a Nebel³

P117 Evolution of clinical trials in onco-hematology in a reference center: does it worth a dedicated structure?

A. Mordohay¹, D. Durand¹, C. Oger¹, L. Ades¹, I. Madelaine¹

P140 Economic impact of fixed-dose nivolumab and pembrolizumab in an oncology institution

V. Pires¹, M. Teixeira¹, R. Varela¹

P149 National Cancer Information System, Ireland – configuring a national drug file and regimen library

C. O'Leary¹, G. Carroll¹, L. O’Farrell¹, C. Donald¹, N. Newcombe¹, P. Heckmann¹

Poster spotlights session

P021 Incidence Of Cisplatin-Induced Nephrotoxicity And Associated Risk Factors: Single-Center Experience

R. Reda¹, A. Anwar², S. Kamal², M. Moneer³, A. Elhemaly⁴

P091 The impact of Covid-19 on mental health professionals in oncology pharmacy

M. Velardi¹, A. Bienert², M. Kuzmanovic³, A. Kokisheva⁴

P133 Advancing Oncology Pharmacy Education in South Africa

R. Kahn¹, A. Orchard¹, M. Vally¹

Posters

Some posters not being displayed at the ECOP 5 congress, abstracts will not appear in the EJOP supplement

Basic research in oncology

P002 Successful introduction of a point mutation into the genome of a primary colon cancer cell line using CRISPR base editing technology

B. Mustafa¹, A. Maghnouj¹, S. A. Hahn¹

P004 Simple Approach to Enhance Green Tea Epigallocatechin Gallate Stability in Aqueous Solutions and it Bioavailability: Experimental and Theoretical Approaches

P. Secretan¹, O. Thirion², H. Sadou Yayé³, T. Damy⁴, A. Astier⁵, M. Paul^1,6, B. Do^1,2

P005 Impact of type I collagen remodeling during aging on the response to vemurafenib in BRAFV600E melanoma cells

L. Florent¹, F. Slimano¹, L. Van Gulick¹, C. Terryn¹, H. Morjani¹, C. Saby¹

P006 Prevalence and Risk factors associated with the use of complementary and alternative medicines in Tunisian cancer patients at Salah Azaiz Institute

A. Khaldi¹, Dr I. Toukebri, Pr A. Ben Said, Pr I. Limayem

P007 Management of buccopharyngeal mucositis induced by anticancer drugs at the Salah Azaiz institute

F. Chelly¹, I. Toukabri¹, A.B. Said^1,2, I. Jmour¹, I. Limayem^1,2

P008 Containment assessment of five commercially available closed system transfer devices (CSTDs) using the 2016 draft NIOSH performance protocol and 2.5% v/v 2-Phenoxyethanol (2-POE) as challenge agent

A. Wilkinson¹, K. E Walker¹, R. Machníková¹, L. Ozolina¹, A. Wallace¹

P009 Impact of the 2019 coronavirus pandemic on cancer treatment in the Calabria Region, Italy

R. F. Scarpelli¹, F. Mortati², F. Festinese³, M. Veraldi¹

P010 TAS-102 with or without bevacizumab in metastatic colorectal cancer

M. Serrano García¹, E. López Aspiroz¹, A. Martínez Hernández¹

P013 Adherence to Intravenous Chemotherapy in Tunisian cancer patients at Salah Azaiez institute

E. Amira¹, I. Tolukebri¹, A. Ben Said¹, A. Gabsi¹, I. Limayem¹

P014 Advanced Microscopical Non-Invasive Examination of the Supposed Migrastatics for Impact on In Vitro Cell Migration

M. Šuráňová¹, M. Zábranská¹, V. Kolínková¹, N. Muchová¹ V. Jůzová², P. Veselý2, R. Chmelík¹

Clinical evaluation

P015 Palbociclib associated neutropenia in clinical practice

A. Soria Martín¹, J. Romero Puerto², A. Moreno Herrera², J. García Marín², M. Fages Pérez², J. R. Ávila Álvarez²

P017 Docetaxel toxicity monitoring in breast cancer: evaluation of professional practices in a French Comprehensive Cancer Center

¹A. Acramel, L. Escalup¹, P. Vaflard², P. Cottu²

P018 Relationship between toxicity and effectiveness of immunotherapy in the treatment of non-small cell lung cancer

A. Valcuende Rosique¹, A. Sánchez Alcaraz¹, A. Ortega Armiñana¹, R. Colom Moreno¹, L. Cebrián Lara¹, C. Pérez Moret¹, A. Sancho Artés¹

P021 Incidence Of Cisplatin-Induced Nephrotoxicity And Associated Risk Factors: Single-Center Experience

R. Reda¹, A. Anwar², S. Kamal², M. Moneer³, A. Elhemaly⁴

P022 Real world data of alk-inhibitors in patients with advanced or metastic non-small cell lung cancer

J. F. Marin Pozo¹, R. Contreras Collado¹, L. Gutierrez Lucena¹, A. Plaza Arbeo¹, V. Cao Viña¹

P023 Pembrolizumab in non-small-cell lung cancer: A systematic review of real life data in Spain

A. M. Ortega Armiñana¹, A. S. Artés¹, M. J. Company Albir¹, A. Valcuende Rosique¹, R. Colom Moreno¹, L. Cebrian Lara¹, A. Sánchez Alcaraz¹

P024 A Review of Immune Checkpoint Inhibitor Therapy in Iceland 2019-2020: Indications and Tolerability. A follow-up study from 2018-2019

T. K. Gudmundsdottir¹, A. Arsælsdottir¹, G. B. Ragnarsson¹

P025 Trastuzumab deruxtecan: real-life use for the treatment of advanced metastatic HER2 positive breast cancer

J.-S. Giraud¹, A. Citerne¹, M. Robert¹, M. Sitbon¹, A.-L. Raso¹, I. Madelaine-Chambrin¹, N. Jourdan-Desrayaud¹

P026 CAR-T cells out of specifications: overview in real life

G. Oka¹, R. Tordjeman¹, I. Madelaine¹, R. de Jorna¹

P027 Effectiveness of venetoclax in the treatment of chronic lymphocytic leukemia: from evidence to experience

A. M. Ortega Armiñana¹, A. S. Artés¹, M. J. Company Albir¹, A. Valcuende Rosique¹, R. Colom Moreno¹, L. Cebrian Lara¹, Agustín Sánchez Alcaraz¹

P028 Azacitidine and Nivolumab in relapsed/refractory angioimmunoblastic T-cell lymphoma: a promising combination

E. Seguin¹, C. Galon¹, A. Bonnin¹, L. Ricard¹, C. Fernandez¹, A.-C. Joly¹, M.-T. Baylatry¹, P. Coppo¹

P029 Frequency of measuring body weight in (sub)populations of patients with cancer treated with chemotherapy

S. Kemps¹, M. Soleyman¹, H. Huls¹, M. Labots², M. Crul¹

P030 Therapeutic management of advanced Hodgkin lymphoma in patients with pulmonary comorbidities

E. Seguin¹, C. Galon¹, A. Bonnin¹, N. Stocker¹, C. Fernandez¹, A.-C. Joly¹

P031 Real-world effectiveness and safety of pembrolizumab in patients with non-small cell lung cancer: a retrospective observational study

MC Martínez Díaz¹, S. Fénix Caballero², C. Moreno Ramos², D. Gil Sierra², AC. Cercós Lleti³

P032 Lung immune prognostic index to predict effectiveness of first-line pembrolizumab in advanced non-small cell lung cancer

MC Martínez Díaz¹, S. Fénix Caballero¹, CM. Dominguez Santana¹, D. Gil Sierra¹, AC. Cercós Lleti²

P034 Real-world use of carfilzomib in patients with relapsed or refractory multiple myeloma

A. Citerne¹, J.-S. Giraud¹, M. Robert¹, A.-L. Raso¹, S. Harel², I. Madelaine-Chambrin¹,

N. Joudan-Desrayaud¹

P035 Analytical, non-clinical, and pharmacokinetic biosimilarity assessment of EG12014, a proposed trastuzumab biosimilar candidate

A.-Ning Lin¹, C.-H. Yang¹, T. Schulze², N Koptelova³, B. Grohmann-Izay²

P036 Car-T: Two-Year outcomes with Axicabtagene Ciloleucel Cells

E. Cataldo¹, F. Zelante¹, F. Chinotti¹, M. Del Vecchio¹, V. Ladisa¹, C. L. Pantano¹

P037 A single experience with palbociclib toxicity requiring dose modifications and its impact on the efficacy

M. Del Vecchio¹, V. Ladisa¹, F. Zelante¹, E. Cataldo¹, F. Chinotti¹, C. L. Pantano¹

P038 The use of intravenous azacitidine : an attractive alternative to be supervised

V. Kamami¹, M. Palamini², J. Rouvet², A. Stamatoullas², F. Basuyau²

P039 Gynecomastia in a male after Imatinib treatment for chronic myeloid leukemia

B. Moukafih¹, S. El marrakchi¹, I. Bennani¹, Y. Elhafidi¹, A. El Kartouti²

P040 Results after discontinuation of pembrolizumab in metastatic melanoma or lung cancer patients: real-word experience

MV. Villacañas Palomares¹, S. Barbadillo Villanueva, CM. Valencia Soto, A. Garcia-Avello Fernandez-Cueto, V. Martínez Callejo, M. Ochagavía Sufrategui, M. Valero Domínguez

P041 Daratumumab, Lenalidomide, and Dexamethasone for relapsed and refractory Multiple Myeloma: Progression free results from a real life analysis

M.E. Uda¹, M. Rivano¹, V. Scintu¹, A.G. Carrucciu¹, P. Serra¹, A. Liguori¹, D. Derudas¹

P042 Real world experience of palbociclib and ribociclib in combination with fulvestrant or with letrozole in the first line treatment of metastatic female breast cancer HER 2

N. Pagnotta¹, F. Ferrante1, D. Mastroianni¹, P. Gagliardi1, E. Rea¹, G. Battista Di Nardo¹, C. Papetti¹

P043 Durvalumab as consolidation therapy in locally advanced unresectable non-small cell lung cancer patients

R. Tamayo Bermejo¹, J. C. Del Río Valencia¹, B. M. Rodríguez¹

P044 Managed of persistent and refractory thrombocytopenia following haematopoietic stem cell transplant

M. C. Sánchez Argaiz¹, S. Sadyrbaeva Dolgova¹, A. García-Avello Fernández-Cueto², M. V. Villacañas Palomares², A. Jiménez Morales¹

P045 Good response to cemiplimab for metastatic cutaneous squamous-cell carcinoma in patient with ulcerative pancolitis

RT. Bermejo¹, JC. Del Río Valencia¹, BM. Rodríguez¹

P046 Real-world clinical practice of first-line palbociclib use in metastatic hormone positive HER negative metastatic breast cancer and comparative with the PALOMA-2 trial

A. Álvarez Manzano¹, L. Abdel-kader Martín¹, M. Fernández González¹, E. Prado Mel1, MD. Vega Coca¹, R. Jiménez Galán¹

P047 Pembrolizumab as first-line treatment for metastatic non-small cell lung cancer: analysis of survival in real life

T. Arrazola Ramírez¹, E. Álvaro Sanz², M. Moreno Santa María², M. Miranda Magaña², M. Garrido Siles³, B. Tortajada Goitia²

P048 Adverse events comparison : CAR-T cells versus bispecific antibodies

J. Berge¹, C. Gazel¹, M. Taphanel¹, M. Fieldes¹, C. Spinau¹, A. Grand¹

P049 Treatments used in patients with metastatic bladder carcinoma

M. José Gándara Ladrón de Guevara¹, MC. Sánchez Argaiz¹, M. del Mar Sánchez Suárez¹,

A. García-Avello Fernández-Cueto², MV. Villacañas Palomares², A. Jiménez Morales²

P050 Effectiveness and safety of durvalumab for advanced non cell lung cancer

L. Ulacia Epelde¹, A. Ros Olaso¹, I. Beristain Aramendi¹, J. Boo Rodriguez¹, T. Gonzalez Fernandez¹, G. Lizeaga Cundin¹, M. Josune Garcia de Andoin Barandiaran¹, G. Lopez Arzoz¹, A. Eceiza Diez1, C. Andueza Granados¹, M. Pilar Bachiller Cacho¹

P051 Impact of Covid-19 in patients with multiple myeloma who are candidates for autologous hematopoietic stem cell transplantation

M. Garrido-Siles¹, M. Carrasco-Gomariz¹, M. Gómez-Delgado¹, A. Jurado-Romero¹, M. Gonzalez-Padilla¹, L. Díaz-Suarez¹, R. Lopez-Escoz¹, I. Moya Carmona¹

P052 Effectiveness and safety of adjuvant treatment of melanoma with checkpoint inhibitors: nivolumab and pembrolizumab

A. Martínez-Suárez¹, C. Castillo-Martín¹, JA. Marcos-Rodríguez¹, J. Cordero-Ramos¹

P053 Study of the frequency of Trastuzumab cardiotoxicity in patients with breast cancer HER2+ at the oncology department of Rouiba Hospital

C. Nehal¹, K. Ait Hammou¹, N. Borsali², S. Bousbia¹, N. Loumi¹

P054 Combined liposomal form of Daunorubicin/Cytarabin: assessment of tolerance, toxicity and medico-economic impact

P. Chambrin¹, F. El Kouari¹, M. Brun¹, E. Vallet¹, A. Chane-Kene¹, L. Hassani¹,

M. Antignac¹, A. Bellanger¹

P055 Proper use of intravenous ferric carboxymaltose (FCM) in hospitalized cancer patients: a retrospective study in real clinical practice

N. Oussedik¹, A. Ginguay³, L. Hirsch², C. Dam¹, K. Ounnoughene¹, D. Borderie³, R. Batista¹, C. Bardin¹

Clinical pharmacy and pharmaceutical care

P060 Indication, Safety and Adherence to Oral Targeted Anticancer Medication

T. K. Gudmundsdottir¹, A. Kristinsdottir Wiium¹, H. Magnusdottir¹

P061 Onco-hematology telepharmacy during the covid-19 pandemic: experience of two years

E. Lopez-Aspiroz¹, M. Serrano-Garcia¹, B. Garcia-de Santiago¹, C. Garcia-Yubero¹, L. Portillo-Horcajada¹, A. Martinez-Hernandez¹

P062 Optimization of oncology patient follow-up through pharmaceutical care and multidisciplinary team working

O. Polinard¹, F. Longton¹

P064 Evaluation of the use of off-label drugs in a comprehensive cancer center

C. Ibáñez-Collado¹, S. Fontanals-Martínez², J. Martínez-Benavides¹,

N. Quer-Margall³, M. Munné-García⁴, R. Mesía Nin⁵, D. Gallardo Giralt⁶, J. M. Ribera Santasusana⁷, O. Montero Pérez¹, A. Clopés Estela⁸

P065 Creatinine determination in platinum-based therapy only necessary once every weeks

S. van der Gaag¹, M. Labots², E. SwArt¹, M. Crul¹

P066 A descriptive, observational and cross-sectional study to determine the prevalence and risks of complementary and alternative medicine use in an adult Dutch (hemato)-oncology population receiving concurrent anti-cancer treatment

M. Rombouts¹, R. Karg¹, M. Crul¹

P067 Results of a 3-years multidisciplinary team including pharmaceutical care for ambulatory blood cancer patients receiving oral antineoplastic drugs

A. le Bozec¹, M. Guedon¹, E. Durot¹, J. Clarenne¹, L. Aubert¹, M. Posta¹, S. Milley¹, L. Evano¹, F. Slimano¹, E. Michelet-Huot¹

P068 Prevalence of Cannabidiol (CBD) consumption and cancer patients’ expectations in one Oncology Day-Hospital: A cross-sectional study

A. le Bozec¹, M. Guedon¹, M. Laurent¹, M. Brugel¹, C. Carlier¹, M. Perrier¹, L. Aubert¹, D. Hettler¹, O. Bouche¹, C. Mongaret¹, F. Slimano¹

P069 Efficacy and safety in evaluating of new drug-eluting method used for Transarterial chemoembolization for hepatocellular carcinoma

I. Bennani^1,2, Y. Hafidi², S. El Marrakchi^1,2, B. Moukafih^1,2, Y. Rahali^3,4, A. El Kartouti⁵

P070 Review and standardization of the hydration protocol for cisplatin-based regimes

V. Pires¹, M. Teixeira¹, R. Varela¹

P071 Niraparib and psychiatric disorders: incidence rate to consider in real life?

C. Konojacki¹, C. Lattard¹, R. Kimibima¹, V. Larbre¹, M.-A. Cerfon¹, A. Cerutti¹, A. Baudouin¹, A. G. Caffin¹, F. Ranchon¹, C. Rioufol¹

P072 Real-life herb-drug interactions (HDI) in cancer patients: a 2-year retrospective study in a university hospital

J. Reverchon¹, J. Oddone¹, E. Dussossoy¹, G. Leboucher¹

P073 Development and feasibility of a clinical pharmacy program integrated into early breast cancer care pathways: the 5P project

A. Baudouin¹, D. Hoegy¹, J. Oddone¹, F. Bel1, E. Dussossoy¹, J. Martin¹, M. Barral¹, C. Mouchoux¹, C. Rioufol¹, F. Ranchon¹

P074 Clinical impact of pharmaceutical care in a multidisciplinary program to secure medication therapy in lymphoma patients treated by immunochemotherapy

M. Albert¹, A. Baudouin¹, MA. Cerfon¹, C. Herledan¹, R. Kimbidima¹, V. Larbre¹, C. Golfier², H. Ghesquiéres², F. Ranchon¹, C. Rioufol¹

P075 Health results of daratumumab in patients with multiple myeloma

J. Garcia Marin¹, P. Villanueva Jimenez¹, M. Fages Perez¹, A. Moreno Herrera¹, Z Martinez-Echevarria Gil-Delgado¹, A. Salguero Olid¹

P076 Efficacy and safety of the ABVD scheme in clinical practice: a retrospective study in a specialty hospital

M. Fages Perez¹, Z Martinez-Echevarria Gil-Delgado¹, A. Moreno Herrera¹, J. Garcia Marin¹, P. Villanueva Jimenez¹

P077 Chimeric Antigen Receptor T Cell Therapy for Aggressive B Cell Lymphomas or Acute Lymphoblastic Leukemia: Incidence and Management of Toxicity in the Real-World Setting

M. Vlachou¹, I. Tzannou², G. Chatzidimitriou¹, V. Papadopoulou¹, P. Stathopoulou¹, G. Stamatiou¹, A. Sakka¹, I. Tsonis², D. Karakasis², I. Baltadakis²

P078 Effect of frailty on the efficacy of first-line pembrolizumab monotherapy for advanced non-small cell lung cancer

R. Jiménez-Galán¹, E. Prado-Mel¹, C. Cruz Barrios¹, S. Sánchez-Ibargüen del Río¹, L. Abdel-Kader-Martín¹, MD. Vega-Coca¹

P079 Effectiveness and safety of new generation antiandrogens in prostate cancer

A. Moreno Herrera¹, Z Martinez-Echevarria Gil-Delgado¹, J. Garcia Marin¹, M. Fages Perez¹, P. Villanueva Jimenez¹

P080 Do patients under anticancer medication know their treatments designation?

E. Amira¹, I. Tolukebri¹, A. BenSaid¹, A. Gabsi¹, I. Blouza¹

P081 Apalutamide and enzalutamide in metastatic hormonosensitive prostate cancer: comparison of adverse effects incidence, tolerability and efficacy

S. Barbadillo Villanueva¹, A. Colon Lopez de Dicastillo², M. Ochagavía Sufrategui¹, MV. Villacañas Palomares¹, S. Lorenzo Martín², A. García-Avello Fernández-Cueto¹, CM. Valencia Soto¹, V. Martínez Callejo¹, E. Parra Alonso², M. Valero Rodríguez¹

P082 Incidence, types and acceptability of pharmaceutical interventions in Salah Azaiz Institute

Y. Trabelsi¹, I. Toukebri¹, I. Jmour¹, H. Bouchemi¹, A. Ben Said¹, I. Limayem¹

P083 Dose adjustment in conditioning chemotherapy before hematopoietic stem cell transplantation in obese patients

MC. Sánchez Argaiz¹, M. del Mar Sánchez Suárez¹, M. José Gándara Ladrón de Guevara¹, A. García-Avello Fernández-Cueto², MV. Villacañas Palomares², A. Jiménez Morales²

P084 Excluding Ranitidine of Premedication Regimens during Paclitaxel Treatment Does Not Raise the Incidence of Hypersensitivity Reactions

D. Huntjens¹, J.W. Vanhommerig², W. van de Veen³, M. Crul⁴

P085 Role of a hospital pharmacist in a prostate cancer multidisciplinay committee

A. Colón López de Dicastillo¹, S. Lorenzo Martín¹, F. Uriarte Estefanía¹, I. Gutiérrez Pérez¹, S. Barbadillo Villanueva², EC. Parra Alonso¹

P086 Real-world evidence of atezolizumab in locally advanced or metastasic urothelial carcinoma

C. Castillo-Martín¹, M. Romero-González¹, A. Martínez-Suárez¹, J. Cordero-Ramos¹, JA. Marcos-Rodríguez¹

P087 Oral drugs in the treatment of oncological patients with short bowel syndrom

I. Stenglova-Netikova¹, O. Bartosova¹

P088 Topical therapy for the treatment of ocular neoplasia: effectiveness and security of compounded 5-fluorouracil eye drops

C. Castillo-Martín¹, A. Martínez-Suárez¹, J. Cordero-Ramos¹, JA. Marcos-Rodríguez¹, R. Castillejo-García¹

P089 The impact of clinical oncology pharmacy in a multidisciplinary healthcare team

A. Hamdi Elmorsi¹, D. Elmotawaa¹, F. Dashti1, F. El Enazy¹

P090 Iatrogenic prevention of anticancer drugs: pivotal role of the pharmaceutical network city-hospital, the experience of a French departmental hospital

V. Guarino¹, Francois Lesauvage¹, William Mina¹, Laurence Gabriel¹

P091 The impact of Covid-19 on mental health professionals in oncology pharmacy

M. Velardi¹, A. Bienert², M. Kuzmanovic³, A. Kokisheva⁴

P092 CDSS alerts for Fluoropyrimidine pre-treatment DPYD screening (SPORE study)

C. Acar¹, B.A.W. Jacobs¹, A. D.R. Huitema¹, D.E.M. van Balen¹

P093 Pharmaceutic-oncological case reports compiled as book

S. Öttl¹, A. Härtel², G. Heyn³, S. Höfel⁴, K. Meier³

P094 Evaluation of nausea control and chemotherapy-induced vomiting in patients undergoing intravenous chemotherapy

F. J. Toja-Camba¹, M. Pereira Vazquez¹, C. Lopez Doldan¹, B. Padron Rodriguez¹, A. Misa García¹, M. E. Gonzalez Pereira¹

P095 Study of interactions with second-generation antiandrogens in prostate cancer patients

J. D. Paradas Palomo¹, R. Tamayo Bermejo¹, M. Espinosa Bosch¹, I. Muñoz Castillo¹

P096 Securing therapy for patients with Leukemia, Myelogenous, Chronic through pharmaceutical care in the hematology department of the Tlemcen hospital Algeria

N. Borsali¹, AF. Bendahmane¹, B. Benzineb¹, S. Guendouz¹, C. Nehal², K. Ait Hammou², N. Achachi³, A. Ayadi⁴, N. Rahmoun⁵, D. Benghebrit⁵, N. Mesli¹

Cytotoxic drug preparation

P098 Subcutaneous daratumumab versus intravenous daratumumab fir the treatment of patients with multiple myeloma: a time, motion and cst assessment study in a general hospital

F. Badibouidi¹, L. Can-Köse¹, L. Dupont¹, C. Truttet², F. Ait-Kac²

P099 Evaluation of Mogamulizumab’s dose-banding in an anticancer drug preparation unit

M. Robert¹, A.-L. Raso¹, J. S. Giraud¹, A. Citerne¹, D. Sankhare¹, I. Madelaine¹, N. Jourdan¹

P100 Transarterial chemoembolization for hepatocellular carcinoma: proposition of new drug-eluting method using a Mixture Design

I. Bennani^1,2, Y. Hafidi², S. El Marrakchi^1,2, B. Moukafih^1,2, Y. Rahali^3,4, A. El Kartouti⁵

P101 Knowledge of the safe handling of medicine used in chemotherapy by pharmaceutical specialists in Latvia

S. Buraja¹, K. Mace², L. Laze², A. Prilina²

P103 Hazardous Drug and Antibiotic Residue Surface Contamination-Is there a need to reduce exposure?

P. Sessink¹, B. Tans², I. Spriet²

P104 Surface contamination with antineoplastic drugs over 8 years in one hospital pharmacy unit working with isolator technology

L. Corre¹, A. Marechal¹, F. Slimano1²

P105 Process improvement strategy for preparation of immunotherapy from freeze-dried BCG in the Central pharmacy of the University Medical Centre Maribor

Z. Cvisic¹, L. Juric¹, K. Zorjan¹, M. Stopinsek¹, A. Strah¹, M. Petre¹

Drug stability

P107 Stability of triple intrathecal standardized preparation of methotrexate cytarabine and methylprednisolone sodium succinate

M. Rivano¹, G. Gongobardo¹, M. Foppoli¹, L. Viganò¹, A. Locatelli¹, M. del Mar Lopez Rodriguez¹, V. Musso¹, G. Calisti¹, G. Perego¹, M. Fazio¹

P108 Study of the relevance of osmolality measurement as a criterion for evaluating drug stability

M. Sacrez¹, E. D’Huart¹, J. Vigneron¹, B. Demoré¹

P109 Extended in-use stability of the generic nab-paclitaxel medicine Pazenir®

R. Terkola¹, C. N. Julia Pietrzak², A. S.a Nebel³

P110 Extended time of use of reconstituted and diluted anticancer drugs: an online software on chemical-physical stability data

M. Chiumente¹, M. Rivano², D. Severino³, S. Bertoli⁴, A.R. Gasbarro⁵, R. Santeramo⁵, A. Pasqualini⁶, R. Provasi⁷, D. Mengato⁸, A. C. Palozzo⁹

P111 Predictive intrinsic stability of Elagolix (EGX), pertinent to drug storage and in-use condition

L. Guichard¹, M. Babiard¹, P. Tilleul¹, H. Sadou Yayé¹

P112 Retrospective and descriptive analysis of short stability antibodies losses, prepared in French centralized preparation unit in and out of clinical trials

S. Lemagner¹, J. Berge¹, M. Mazire¹, C. Gazel¹, M. Taphanel¹, M. Fieldes¹, C. Spinau¹, A. Grand¹, S. Perriat¹

P113 Physicochemical and biological stability study of mogamulizumab in diluted solution

E. Pinet¹, Lionel Barty¹, A-B. Bouvrain¹, F. Lecheviller¹, N. Vaillant¹, N. Jourdan¹, H. Sauvageon¹, I. Madelaine¹

Organisation and management

P115 Outpatient administration of blinatumomab for acute lymphocytic leukemia

M. Victoria Villacañas Palomares¹, S. Barbadillo Villanueva¹, CM. Valencia Soto¹, A. Garcia-Avello Fernandez-Cueto¹, V. Martinez Callejo¹, M. Ochagavia sufrategi¹, M. Valero dominguez¹

P116 Environmental contamination of a dematerialized chemotherapy production unit: current situation and future prospects

Cyrielle Navaud¹, M. Teytaud¹, B. Atge, C. Donamaria¹, B. Lortal¹, L. Jordono¹

P117 Evolution of clinical trials in onco-hematology in a reference center: does it worth a dedicated structure?

A. Mordohay¹, D. Durand¹, C. Oger¹, L. Ades¹, I. Madelaine¹

P120 Personalized pharmacy center of Ukraine. Exceptional opportunities for patients

V. Zapotochna¹

P121 Risk mapping in a chemotherapy preparation unit (CPU) using a tool developed by a French regional health agency

E. Feuerstein¹, C. Bedoucha¹, M. Gayral¹, R. Dulin¹, A-C. Marion¹

Other

P125 Instrumental radiopharmacy – a step in reduction of occupational dose at the department of nuclear medicine

M. Budinsky¹, Z. Dulikova²

P126 Psychological impact of Covid-19 pandemic in cancer patients at the Institute of Salah Azaiz

F. Chelly¹, I. Toukabri¹

P127 Chemfort® Closed System Transfer Device (CSTD) Extends Practical In-Use Shelf Life to 28 Days After First Puncture of Non-Preserved Single-Use Vials

R. Terkola¹, A.S. Nebel, C. N. J. Pietrzak

P128 3D Printing of personalized medicine

K. Karacic¹, Dr. U. Lösch¹

P129 Providing oncology pharmacy services during the coronavirus pandemic. French Society for Oncology Pharmacy (Société Française de Pharmacie Oncologique-SFPO) guidelines writing and evaluation

B. Pourroy^1,2, C. Bardin^2,3, R. Chevrier^2,4, C. Rioufol^2,5, F. Slimano^2,6, J.F. Tournamille^2,7, I. Madelaine^2,8

P130 Providing oncology pharmacy services to Ukrainian refugees suffering from cancer. Elaboration of the guidelines for pharmaceutical care and information leaflets on dispensing of oral cancer drugs in the Ukrainian language provided by French Society for Oncology Pharmacy (Société Française de Pharmacie Oncologique-SFPO)

B. Pourroy^1,2, C. Bardin^2,3, R. Chevrier^2,4, C. Rioufol^2,5, F. Slimano^2,6, J.F. Tournamille^2,7, I. Madelaine^2,8

P132 The application of STIBS in cancer gene therapy, immuno-oncology, clinical trials and drug production laboratories

Molenda¹ ,M. Adamski¹

P133 Advancing Oncology Pharmacy Education in South Africa

R. Kahn¹, A. Orchard¹, M. Vally¹

P134 Cancer treatments: A Vademecum for healthcare professionals

M. Veraldi¹, A. Ossato², S. Michielan³, M. Rivano⁴, S. Sanogo⁵, M. Zuccarelli⁶, S. Masucci⁷, S. Bertoli⁸, O. Bernocchi⁹, M. Chiumente¹⁰, A. Palozzo¹¹

P135 Increasing acceptance of annual in-house training for CMR substances: change from face-to-face to webinar

K. Tiede¹, C. Deiss¹, H. Lueck¹

Pharmacoeconomics

P136 Nivolumab & Pembrolizumab: the economic impact of a fixed-dose strategy

M. Hainaut¹, A. Fillatre¹, A. Abdaoui¹, P. Saint-Germain¹, A. Houbert¹

P137 Effectiveness and cost-effectiveness of durvalumab after chemo-radiotherapy in non-small cell lung cancer

¹J. Fco Marin Pozo, ¹R. Contreras Collado, ¹L. Gutierrez Lucena, ¹V. Cao Vina, ¹A. Plaza Arbeo

P138 Influence of a durvalumab use protocol based on patient weight on treatment costs

¹R. Contreras Collado, ¹J. Francisco Marin Pozo, ¹L. Gutierrz Lucena, ¹V. Cao Viña, ¹A. Palza Arbeo

P139 A comparison between cost perception of anticancer treatment by patients under chemotherapy and those under targeted therapy or immunotherapy in Tunisian cancer patients at Salah Azaiez institute

E. Amira¹, I. Tolukebri¹, A. BenSaid¹, A. Gabsi¹, I. Blouza¹

P140 Economic impact of fixed-dose nivolumab and pembrolizumab in an oncology institution

V. Pires¹, M. Teixeira¹, R. Varela¹

Pharmacokinetics and therapeutic drug monitoring

P141 Individual dosing of carboplatin according to five formula used in a cohort of patients with ovarian cancer in real life

A. Hassan¹, R. Kimbidima¹, A. Cerutti¹, V. Larbre¹, A. Baudouin¹, N. Vantard¹, B. You², A. Carrot³, C. Rioufol¹, F. Ranchon¹

P144 DPYD gene mutation frequency in oncology patients in a tertiary hospital

RT. Bermejo¹, B. Mora Rodríguez¹, M. Espinosa Bosch¹, I. Muñoz Castillo¹

Quality Management

P146 Use of failure modes, effects and criticality analysis (FMECA) to improve safety in the injectable chemotherapy production process

F. Badibouidi¹, L. Köse¹, E. Misat¹, O. Certano¹, C. Zuppetti¹, C. Truttet², F. Ait-Kaci²

P147 ESOP’s yellow hand: are the pharmaceutical laboratories really devoting all the necessary?

F. Badibouidi¹, L. Can-Köse¹, L. Dupont¹, A. Jimenez¹, D.-L. Tran¹

P148 Quality and economic value of returned unused oral targeted anticancer medication from patients and measures to reduce medication waste

T. K. Gudmundsdottir¹, H. Johannsdottir¹, A. I. Gunnarsdottir¹, H. Magnusdottir¹

P149 National Cancer Information System, Ireland – configuring a national drug file and regimen library

C. O'Leary¹, G. Carroll¹, L. O’Farrell¹, C. Donald¹, N. Newcombe¹, P. Heckmann¹

P150 Improving the safety on the pathway of patients receiving CAR-T cells: risk analysis at the Pitié-Salpêtrière hospital

D. le Febvre de Nailly¹, C. Metz¹, M. Dhib-Charfi¹, P. Tilleul¹, F. Charbonnier-Beaupel¹

P151 Destruction of chemotherapy preparations after non-compliant analytical control: what types of errors and for which molecules?

A-L. Raso¹, M. Robert¹, J-S. Giraud¹, A. Citerne¹, I. Madelaine¹, N. Jourdan¹

P152 A simulation tool to evaluate experimental drugs preparation practices

J. Convert¹ V. Gomes¹, V. Schwiertz¹, C. Herledan¹, A. Guerin-Rollin¹, A. Caffin¹, A. Baudouin¹, N. Vantard¹, F. Ranchon¹, C. Rioufol¹

P153 Implementation of an Advanced Therapy Medical Product (ATMP, Tabelecleucel) in a University Teaching Hospital in France. Application of the Preliminary Risk Analysis Method

B. Fabri¹, G. Sicard¹, R. Fanciullino², B. Deluca¹, N. Ausias³, M. Montana³, L. Gauthier Villano¹, B. Pourroy¹

P154 Implementation of the Advanced Therapy Medical Product (ATMP) Tisagenlecleucel in a University Teaching Hospital in France. Application of the Preliminary Risk Analysis Method

B. Fabri¹, G. Sicard¹, B. Deluca¹, N. Ausias², M. Montana², L. Gauthier Villano¹, B. Pourroy¹

P155 Securizing advanced therapy medicinal product (ATMP) tabelecleucel delivery

B. Fabri¹, G. Sicard¹, R. Fanciullino², N. Ausias³, M. Montana¹, L. Gauthier Villano¹, B. Pourroy¹

P156 Securing the administration of chemotherapy prepared in syringes for administration by electric syringe pump

M. Benmalek¹, A. Crutti¹, V. Larbre^1,2, A. Baudouin¹, R. Kimbidima¹, M.A. Cerfon¹, F. Ranchon^1,2, N. Vantard¹, C. Rioufol^1,2